Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Panel to Review Kissei’s Uterine Fibroid Drug, 3 More NMEs on December 3
Japan’s health ministry will convene the Pharmaceutical Affairs Council’s First Committee on Drugs on December 3 to review a slate of products that includes Kissei Pharmaceutical’s uterine fibroid drug linzagolix, known as Yselty overseas. Kissei’s candidate — a GnRH antagonist…
To read the full story
Related Article
- MHLW Panel Green-Lights Approval for Kissei’s Uterine Fibroid Drug, 3 More NMEs
December 4, 2025
- Ultragenyx Japan Seeks Conditional Approval of Triheptanoin for LC-FAOD
August 12, 2025
- Takeda Seeks Pediatric Nod for cTTP Drug Adzynma in Japan
March 28, 2025
- Kissei Files Linzagolix for Uterine Fibroids in Japan
February 27, 2025
- Kerendia Filed for Chronic Heart Failure in Japan: Bayer
February 17, 2025
- Santen Files RVL Pharma’s Droopy Eyelid Drug in Japan
December 27, 2024
REGULATORY
- Japan Panel Again Defers Male HPV Shots amid Cost-Effectiveness Concerns
October 9, 2026
- Takaichi Defends Off-Year Drug Price Revisions as DPP Calls for Abolition
October 9, 2026
- Japan Orders Contraindication for Adlumiz-Noxafil Combination
October 9, 2026
- Imcivree, Hibsago Get Chuikyo Nod for Home Self-Injection
October 9, 2026
- Provider-Payer Tug-of-War Takes Shape over FY2027 Drug Price Revision
October 8, 2026
Japan’s plasma-derived product industry is approaching a turning point as the government prepares to step in with unprecedented support for…
The Wednesday TableShe had been on virtual calls since eight in the morning. The screen glowed. Her eyes burned. Plugged into Teams across time zones, she was digitally connected yet entirely isolated from the reality of Japan’s pharma market.She needed…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…